SYBLEU

SYBLEU Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of SYBLEU (SYBE) as of Nov 2, 2026 is -4.71. In the previous year, Net Debt to Free Cash Flow Ratio was -0.93 — a change of 405.66% (lower).

Net Debt/FCF

-4.71

YoY

405.66%

Last updated:

Net Debt to Free Cash Flow Ratio of SYBLEU is 2023 -4.71 . Net Debt to Free Cash Flow Ratio of SYBLEU was 2022 -0.93 . It decreases by 405.66% lower compared to the previous year.

The SYBLEU Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2020
-0.98 USD
Jan 1, 2021
0.06 USD
Jan 1, 2022
-0.93 USD
Jan 1, 2023
-4.71 USD
The SYBLEU Net Debt/FCF history
YEARNet Debt/FCFYoY
-4.71+405.66%
-0.93-1,622.70%
0.06-106.21%
-0.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SYBLEU Stock analysis

What does SYBLEU do? SYBLEU Inc develops regenerative medical applications focused on therapies for human and animal health, medical devices, and clinical diagnostics. The company generates revenue through the sale or licensing of its developed applications after completing Phase I or Phase II clinical trials, or by advancing them to Phase III trials. It also develops disposable medical devices and explores artificial intelligence and machine learning applications in clinical diagnostics. SYBLEU Inc targets the healthcare sector with its innovative medical solutions. The firm's primary products include therapies for human and animal health, medical devices, and clinical diagnostics. It also develops drugs for treating cancer in companion animals, leveraging artificial intelligence and machine learning in its diagnostic processes. SYBLEU Inc's business model relies on advancing its applications through clinical trials to either secure licensing deals or commercialize its products directly. SYBLEU Inc's target market segments are healthcare providers, veterinary clinics, and medical device manufacturers seeking innovative regenerative therapies and diagnostic tools. The company's focus on companion animal cancer treatments and AI-enhanced diagnostics positions it within specialized segments of the medical industry. Its development of disposable medical devices further expands its reach into the broader healthcare market. SYBLEU is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SYBLEU stock

Net Debt to Free Cash Flow Ratio of SYBLEU is -4.71 in 2023.

Net Debt to Free Cash Flow Ratio of SYBLEU changed from -0.93 to -4.71, representing a 405.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio SYBLEU since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's SYBLEU with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SYBLEU

All Key Metrics — SYBLEU